Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Immuno-oncology drug development goes global

  1. Jia Xin Yu

    1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Vanessa M. Hubbard-Lucey

    1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Jun Tang

    1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Immunotherapy has become an essential pillar for cancer treatment, and the drug development space continues to attract numerous organizations that aim to transform scientific innovation into practice-changing cancer drugs. In the current analysis, we provide the latest update of the global immuno-oncology (IO) drug pipeline development, comparing our first survey conducted in September 2017 with our most recent survey conducted in August 2019.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 899-900 (2019)

doi: https://doi.org/10.1038/d41573-019-00167-9

Updates & Corrections

  • Correction 22 November 2019: In the original version of Figure 3, the colours of the bars representing cell therapies and cancer vaccines were interchanged for some of the countries. The figure has been replaced to reflect the correct number of agents in both of these categories.

Supplementary Information

  1. Supplementary figures

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links